Charles Wykoff, MD, PhD, joins Diane Bovenkamp, PhD, for a Macular Chat hosted by BrightFocus Foundation and ASRS to discuss the current landscape and future of wet age-related macular degeneration (AMD) treatments. Wykoff explains the differences between wet and dry AMD, emphasizes the importance of early detection and dilated eye exams, and breaks down anti-VEGF injections as the gold standard for treating wet AMD. He addresses access challenges like step therapy and the Avastin shortage, and highlights promising research into gene therapies, self-injectables, and longer-lasting treatments. The takeaway: while injections are “forever for now,” the future of AMD care is bright.